ORP-101

DB16072InvestigationalSmall molecule

ORP-101 is under investigation in clinical trial NCT04129619 (A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)).

Mechanism: Pharmacologically active on Kappa-type opioid receptor and Mu-type opioid receptor
Curator reviewed
Formula / weight: C₆₀H₈₄N₂O₈ · 961.338 g/mol (avg)
Also known as: Buprenorphine dimer
Code names: ORP-101

Resolves to

Compound

UNIISE6KE496VOCAS1820753-68-1

Structure

InChIKeyLEQOVFCHMOTJKU-WJVXOHEGSA-NSMILES

[H][C@@]12OC3=C4C(C[C@H]5N(CC6CC6)CC[C@@]14[C@@]51CC[C@@]2(OC)[C@]([H])(C1)[C@](C)(O)C(C)(C)C)=CC=C3OCCOC1=CC=C2C[C@H]3N(CC4CC4)CC[C@]45C2=C1O[C@@]4([H])[C@]1(CC[C@@]35C[C@]1([H])[C@](C)(O)C(C)(C)C)OC

Targets

P41145OPRK1P35372OPRM1

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with ORP-101, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account